Novartis signs deal to boost cell therapy portfolio
ZURICH, Sept 6
ZURICH, Sept 6 (Reuters) - Swiss drugmaker Novartis AG said on Friday it had signed a licensing and research deal that could boost its ability to develop innovative cell-based therapies for conditions where little treatment is currently available.
The maker of blockbuster blood pressure drug Diovan said it would use a stem-cell based platform developed by U.S.-based biopharmaceutical company Regenerex to help broaden its cell therapy portfolio.
Timothy Wright, head of development at Novartis Pharmaceuticals, said the agreement would support Novartis' leadership position in cell therapy.
- Bodies found trapped inside sunken South Korean ferry: coastguard |
- Vice-principal of South Korea school in ferry disaster commits suicide |
- Special Report: How the U.S. made its Putin problem worse
- Israel space project gets $16 million boost from casino mogul Adelson
- All 338 Korean students, teachers rescued from sinking ferry - school official